Use of Let-7g to down regulate NS5B gene, core protein and viral load of hepatitis C virus

Patent metadata

Field	Value
Publication number	US-9738942-B2
Application number	US-201415027692-A
Country	US
Kind code	B2
Filing date	Mar 31, 2014
Priority date	Oct 11, 2013
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

A method for evaluating the therapeutic efficacy of interferon (IFN)/ribavirin (RBV) for hepatitis C is disclosed. The method includes the steps of providing a specimen; mixing the specimen, a primer of a miRNA Let-7g and a poly-chain reaction (PCR) reagent together; and evaluating the efficacy of IFN/RBV on inhibiting a hepatitis C virus according to the expressing level of the miRNA Let-7g in the specimen detected by the PCR reagent.

First claim

What is claimed is:

1. A method for treating hepatitis C of a patient according to evaluating a therapeutic efficacy of interferon (IFN)/ribavirin (RBV) on inhibiting a hepatitis C virus, comprising the steps of:
providing a specimen of the patient containing a microRNA Let-7g (miRNA Let-7g);
mixing the specimen containing the miRNA Let-7g, a primer of the miRNA Let-7g and a polymerase chain reaction (PCR) reagent altogether;
performing a quantitative real time PCR on the miRNA Let-7g using the primer and the PCR reagent to obtain a CT(Let-7g) value:
evaluating the therapeutic efficacy of IFN/RBV on inhibiting the hepatitis C virus according to an expressing level of the miRNA Let-7g in the specimen, wherein the expressing level of miRNA Let-7g is represented by LOG 10(2 −ΔCT ), ΔCT=CT(Let-7g)−CT (an internal control), and when the expressing level of the miRNA Let-7g is more than 1.14 the therapeutic efficacy of IFN/RBV on inhibiting the hepatitis C virus in the specimen is confirmed; and
administering an effective amount of IFN/RBV to the patient that the therapeutic efficacy of IFN/RBV on inhibiting the hepatitis C virus is confirmed.

2. The method as claimed in claim 1 , wherein the primer is a pair of primers.

3. The method as claimed in claim 1 , wherein the internal control is snU6B.

Assignees

• Univ Kaohsiung Medical

Inventors

• Dai Chia-Yen
• Yu Ming-Lung
• Chuang Wan-Long
• Chou Wen-Wen

Classifications

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• A61K38/21 Primary

  Interferons {[IFN]} · CPC title

• A61K31/7056

  containing five-membered rings with nitrogen as a ring hetero atom · CPC title

• G01N33/5767

  non-A, non-B hepatitis · CPC title

• C12Q1/707 Primary

  non-A, non-B Hepatitis, excluding hepatitis D · CPC title